Elevar to resubmit liver cancer drug to FDA
10 Jul 2024
Elevar Therapeutics announced its plans to resubmit its application to the FDA for rivoceranib in combination with camrelizumab as a first-line treatment for unresectable hepatocellular carcinoma (uHCC).
The follows a Type A meeting with the FDA on July 2, 2024, where the agency confirmed that the resubmission can proceed without delay and that additional GMP and Bioresearch Monitoring (BIMO) inspections may occur post-resubmission.
The original NDA, submitted in May 2023, was met with a complete response letter citing GMP deficiencies at China-based partner Jiangsu Hengrui Pharma's facility and incomplete BIMO clinical inspections due to FDA travel restrictions. There were no issues related to clinical data or the rivoceranib manufacturing site.
Elevar intends to resubmit the NDA promptly, including data from the CARES-310 study, which showed a median overall survival of 23.8 months for patients with uHCC.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.